India Prime Minister Modi Discusses Stem Cell Therapy with Dr. Anand Srivastava of GIOSTAR

“The world is experiencing a critical shortage of blood the WHO Global Study reveals. Strategic investments are needed in many low-income and middle-income countries to expand national transfusion services, blood management systems, and alternatives to blood transfusions.”

ATLANTA (PRWEB)
January 23, 2020

GIOSTAR/HEAMGEN has developed and secured patented technology to manufacture lifesaving mature red blood cells from stem cells. The red blood cells are made utilizing a bioreactor that permits the production of mature red blood cells, under strictly controlled conditions, for transfusion therapy and replaces the need for a human blood donor. GIOSTAR/HEAMGEN mature red blood cells are safe and not compromised by inadequate pathogen detection and inactivation of diseases such as hepatitis C, HIV, hepatitis B and syphilis. The red blood cells are O-Negative (Universal Donor) to eliminate incompatibility and allosensitization reactions. Trauma situations often do not allow for adequate blood typing due to time restrictions, so the GIOSTAR/HEAMGEN red blood cells address that need effectively.

“There are three main problems for blood transfusions,” stated Dr. Anand Srivastava, founder and CEO of GIOSTAR. “First we have to match the blood type. Second, there’s not enough blood available every single time. And third, when we transfer blood from one person to another person, there is always a chance of the transfer of disease.”

Watch a feature interview with Dr. Anand Srivastava on The DM Zone with host Dianemarie Collins.

The World Health Organization (WHO) published the first detailed analysis on the global supply and demand for blood in October 2019 and found that 119 out of 195 countries do NOT have enough blood in their blood banks to meet hospital needs. In those nations, which include every country in central, eastern, and western sub-Saharan Africa, Oceania (not including Australasia), and south Asia are missing roughly 102,359,632 units of blood, according to World Health Organization (WHO) goals. While total blood supply around the world was estimated to be around 272 million units, in 2017, demand reached 303 million units. That means the world was lacking 30 million units of blood, and in the 119 countries with insufficient supply, that shortfall reached 100 million units.

The global market opportunity for GIOSTAR/HEAMGEN technology presents not only a profitable and scalable business opportunity but also a significant social and environmental impact. The global market is estimated to be at least $ 85 Billion/year.

GIOSTAR/HEAMGEN has identified early entry global markets to include Military, Trauma, Asia (replace Hepatitis C contaminated blood products), Africa (AIDS contaminated blood), Newborns, Thalassemia patients, Allosensitized sickle cell disease patients. South Sudan was found to have the lowest supply of blood, at 46 units per 100,000 people. In fact, the country’s need for blood was deemed 75 times greater than its supply. In India, which had the largest absolute shortage, there was a shortfall of nearly 41 million units, with demand outstripping supply by over 400 percent. Strategic investments are needed in many low-income and middle-income countries to expand national transfusion services and blood management systems. Oncology is a major user of blood transfusion but if countries don’t have the capacity to manage the bulk of oncology, it will limit complex surgery options.

GIOSTAR/HEAMGEN has acquired the exclusive license to the patent for the technique for stem cell proliferation from University of California San Diego (UCSD). The founding team of GIOSTAR/HEAMGEN is comprised of the scientists and clinicians who were involved in creating the Intellectual Property at UCSD and has already achieved PROOF OF CONCEPT – the optimized lab scale proliferation of mature red blood cells – at UCSD as part of their research.

GIOSTAR/HEAMGEN is currently looking for strategic partnerships (Contact Doug@DMProductionsLLC.com) to accelerate the development of donor-independent red blood cells manufacturing capabilities and advance the proof of concept work already done (patented) around the manufacture of safe, universal donor, human red blood cells. GIOSTAR/HEAMGEN will also develop a full automated proprietary bioreactor using robotic technology to produce abundant quantities of red blood cells with a goal for cost-effective commercialization of fresh, human, universal donor Red Blood Cells (RBCs).

ABOUT GIOSTAR

Dr. Anand Srivastava is a Chairman and Cofounder of California based Global Institute of Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California, (U.S.A.). The company was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world such as Parkinson’s, Alzheimer’s, Autism, Diabetes, Heart Disease, Stroke, Spinal Cord Injuries, Paralysis, Blood Related Diseases, Cancer and Burns. GIOSTAR is a leader in developing most advance stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Company’s primary focus is to discover and develop a cure for human diseases with the state of the art unique stem cell based therapies and products. The Regenerative Medicine provides promise for treatments of diseases previously regarded as incurable.

GIOSTAR is world’s leading Stem cell research company involved with stem cell research work for over a decade. It is headed by Dr Anand Srivastava, who is a pioneer and a world-renowned authority in the field of Stem Cell Biology, Cancer and Gene therapy. Several governments and organizations including USA, India, China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others seek his advice and guidance on drafting their strategic and national policy formulations and program directions in the area of stem cell research, development and its regulations. Under his creative leadership, a group of esteemed scientists and clinicians have developed and established Stem Cell Therapy for various types of autoimmune diseases and blood disorders, which are being offered to patients in USA and soon it will be offered on a regular clinical basis to the people around the globe.

Share article on social media or email:

Dr. Alejandro Badia

Hand specialists are also experts in microsurgical techniques, having undergone additional, rigorous training in repair of the hand’s minute blood vessels and nerves which requires the use of an operating microscope.

MIAMI (PRWEB)
January 23, 2020

“It’s complicated.” The phrase may apply to some human relationships but certainly holds true for the complex architecture providing function to a person’s hand, wrist, arm and shoulder. “Which is why patients should contact an experienced upper-limb specialist – not just an orthopedic surgeon — when anything goes wrong up or down this superhighway of interconnected bones, joints, tendons, ligaments, muscles and nerves,” says renowned hand and upper-limb surgeon Alejandro Badia MD. Dr. Badia and many of his colleagues note that our patients are often unaware that the specialty of hand surgery even exists and often ask, “What type of issues do you treat?”. This fact even led to the development of ISSPORTH (International Society of Sport Traumatology of the Hand), where a group of colleagues in Europe noted that many elite athletes seemed unaware of the specialties’ importance when it came to assessing and treating their sports-related wrist or elbow issues. Badia served as the international societies first president in 2011-12.

Of course, orthopedic surgeons, in general, address injuries and diseases of the musculoskeletal system. However, “hand specialists are also experts in microsurgical techniques, having undergone additional, rigorous training in repair of the hand’s minute blood vessels and nerves which requires the use of an operating microscope” explains Dr. Badia. Arthroscopic and minimally invasive techniques involving the wrist, hand and elbow are also the domain of the hand surgeon, and like Badia, many also focus on the shoulder due to its importance in controlling the entire upper limb function by placing the hand in space.

Badia completed fellowships in hand and trauma surgery following four years of orthopedic and surgical residency at New York University, preceded by a general surgery internship at the historic Bellevue Hospital.

German philosopher Immanuel Kant referred to the critical importance of the human hand by calling it “the visible part of the brain.” The same description could hold true for the wrist, arm and shoulder, which provide the necessary fulcrums and levers to give the hand motion and the strength to grasp, hold, lift, turn, work and play. The shoulder, for example, is one of the most complex joints in the body, powered by a collection of muscles and tendons (rotator cuff) and able to assume as many as 1,000 different positions.

The capabilities of the upper limbs are what set aside humans from other animals, states Dr. Badia, whose professional memberships include the American Society for Surgery of the Hand (ASSH) and multiple international orthopedic, hand and arthroscopic surgical societies. The human thumb function specifically separates us from other simians, for example.

“Considering the upper anatomy’s importance to overall quality of life, why wouldn’t patients contact an available surgeon who specializes in the care of the upper extremity for treatment of problems, including pain, that affect the function of their hand, wrist, arm or shoulder?”

Emergence of hand and upper-limb surgery as a subspecialty of orthopedic surgery is fairly recent, dating primarily to World War II when large numbers of battle-related hand injuries brought together a variety of specialists – general, orthopedic, vascular and plastic surgeons, as well as neurosurgeons – to treat and return function to soldiers’ hands. This multidisciplinary approach served as a model for development of special centers – and, later, professionals — for care of the hand.

Today’s rapid, ongoing changes in medical and surgical procedures for musculoskeletal disorders and development of new biomaterials — like tissue-engineered substitutes as replacements for skin or tendon grafts – to repair joints, ligaments and muscles make subspecialization within the field of orthopedic surgery almost mandatory. “No one physician can know and learn about study findings and advancements affecting every area of the skeleton,” Dr. Badia says.

As founder and medical director of the Florida-based Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic, Dr. Badia speaks from experience, having become internationally known for his treatment of a wide array of upper-limb disorders and injuries, including complex trauma, tennis elbow, carpal tunnel syndrome, ulnar nerve entrapment, shoulder impingement, wrist disorders, distal radius fractures, post-injury reconstruction and outpatient upper limb joint replacement. His patients have included well known sports professionals and corporate executives from Europe, South America and even Asia.

“Musculoskeletal pain is a leading reason why people visit doctors,” Dr. Badia says. “That’s why it is important patients select the right specialist to ensure quick, accurate diagnosis and receive the optimal therapy for resolving their problem.”

Just because a patient sees a hand and upper-limb surgeon – or any orthopedic surgeon, for that matter – does not mean surgery will be the recommended course of action. Conservative approaches, including anti-inflammatory medications, corticosteroid injections, splinting, physical therapy, or recommended stretching and home exercises, are often first line of treatment for many musculoskeletal conditions.

Surgery is only required when debilitating pain or disease persists, says Dr. Badia, who is also expert in use of alternative, nonsurgical approaches like orthobiologics – the harnessing of a person’s own biologic substances, including blood platelets and adult (mesenchymal) stem cells — to mitigate inflammation, relieve chronic musculoskeletal pain and repair orthopedic injuries when standard therapies fail.

Dr. Badia’s advice to patients:

• Do the research. Learn about the training and experience of specific doctors and clinics before selecting.
• Match the specialist with the problem. Consider a 2nd opinion with an upper-limb specialist should the problem involve the hand or upper extremity.
• Ask questions about treatment options.

Enhance the potential for treatment success by following the specialist’s directions.

“As specialists and subspecialists in orthopedics, we do more than mend bones and fix joints,”

Dr. Badia adds. “We apply the latest therapies to treat a myriad of disorders affecting nerves, muscles, ligaments and other structures of the musculoskeletal system.”

Alejandro Badia, MD, FACS, internationally renowned hand and upper-limb surgeon and founder of Badia Hand to Shoulder Center and OrthoNOW®, a walk-in orthopedic care clinic. He is a member of the American Society for Surgery of the Hand, American Association for Hand Surgery and the American Academy of Orthopedic Surgeons and an honorary member of many international professional hand societies. Dr. Badia specializes in treating all problems related to the hand and upper extremities, including trauma, sports injury, joint reconstruction, nerve injuries and arthroscopic surgeries. Go to OrthoNOWcare.com and drbadia.com.